JP2005508916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508916A5 JP2005508916A5 JP2003531968A JP2003531968A JP2005508916A5 JP 2005508916 A5 JP2005508916 A5 JP 2005508916A5 JP 2003531968 A JP2003531968 A JP 2003531968A JP 2003531968 A JP2003531968 A JP 2003531968A JP 2005508916 A5 JP2005508916 A5 JP 2005508916A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- composition according
- replication
- dna plasmid
- defective adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 113
- 241000701161 unidentified adenovirus Species 0.000 claims 73
- 239000013612 plasmid Substances 0.000 claims 72
- 230000003834 intracellular effect Effects 0.000 claims 60
- 108090000288 Glycoproteins Proteins 0.000 claims 49
- 102000003886 Glycoproteins Human genes 0.000 claims 49
- 108020004707 nucleic acids Proteins 0.000 claims 49
- 102000039446 nucleic acids Human genes 0.000 claims 49
- 150000007523 nucleic acids Chemical class 0.000 claims 49
- 230000004927 fusion Effects 0.000 claims 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims 40
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 39
- 230000002068 genetic effect Effects 0.000 claims 32
- 102000004961 Furin Human genes 0.000 claims 30
- 108090001126 Furin Proteins 0.000 claims 30
- 238000003776 cleavage reaction Methods 0.000 claims 30
- 230000007017 scission Effects 0.000 claims 30
- 230000002950 deficient Effects 0.000 claims 27
- 230000010076 replication Effects 0.000 claims 27
- 108010061100 Nucleoproteins Proteins 0.000 claims 20
- 102000011931 Nucleoproteins Human genes 0.000 claims 20
- 230000037452 priming Effects 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 241001115401 Marburgvirus Species 0.000 claims 13
- 241001115402 Ebolavirus Species 0.000 claims 10
- 210000004899 c-terminal region Anatomy 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 230000037430 deletion Effects 0.000 claims 10
- 238000012217 deletion Methods 0.000 claims 10
- 108020004705 Codon Proteins 0.000 claims 9
- 206010023927 Lassa fever Diseases 0.000 claims 9
- 241000700605 Viruses Species 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 230000028993 immune response Effects 0.000 claims 6
- 102000007999 Nuclear Proteins Human genes 0.000 claims 5
- 108010089610 Nuclear Proteins Proteins 0.000 claims 5
- 230000009977 dual effect Effects 0.000 claims 5
- 101900102527 Lake Victoria marburgvirus Nucleoprotein Proteins 0.000 claims 4
- 241000271566 Aves Species 0.000 claims 2
- 101710141454 Nucleoprotein Proteins 0.000 claims 2
- 241000700618 Vaccinia virus Species 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 238000002649 immunization Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32647601P | 2001-10-01 | 2001-10-01 | |
| PCT/US2002/030251 WO2003028632A2 (en) | 2001-10-01 | 2002-09-24 | Development of a preventive vaccine for filovirus infection in primates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005280131A Division JP4198148B2 (ja) | 2001-10-01 | 2005-09-27 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508916A JP2005508916A (ja) | 2005-04-07 |
| JP2005508916A5 true JP2005508916A5 (enExample) | 2006-10-12 |
Family
ID=23272371
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003531968A Pending JP2005508916A (ja) | 2001-10-01 | 2002-09-24 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
| JP2005280131A Expired - Lifetime JP4198148B2 (ja) | 2001-10-01 | 2005-09-27 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005280131A Expired - Lifetime JP4198148B2 (ja) | 2001-10-01 | 2005-09-27 | 霊長類におけるフィロウイルス感染に対する予防ワクチンの開発 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US7635688B2 (enExample) |
| EP (1) | EP1504112A4 (enExample) |
| JP (2) | JP2005508916A (enExample) |
| AT (1) | ATE396739T1 (enExample) |
| AU (1) | AU2002327049B2 (enExample) |
| CA (4) | CA2462455C (enExample) |
| DE (1) | DE60226911D1 (enExample) |
| ES (1) | ES2307093T3 (enExample) |
| WO (1) | WO2003028632A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004262022B2 (en) * | 2003-08-01 | 2010-10-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Accelerated vaccination |
| CN1913919B (zh) * | 2003-09-15 | 2011-10-19 | 美国政府健康及人类服务部 | 基于hiv多进化枝的env的hiv疫苗 |
| CN1922308A (zh) | 2004-02-23 | 2007-02-28 | 克鲁塞尔荷兰公司 | 病毒纯化方法 |
| US7504243B2 (en) | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
| WO2005110492A2 (en) * | 2004-04-12 | 2005-11-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of using adenoviral vectors to induce an immune response |
| EP2397490B1 (en) | 2004-07-16 | 2013-09-04 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine constructs and combinations of vaccines designed to improve the breadth of the immune response to diverse strains and clades of HIV |
| WO2006037038A1 (en) * | 2004-09-27 | 2006-04-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Optimized vaccines to provide protection against ebola and other viruses |
| ATE412737T1 (de) | 2005-04-11 | 2008-11-15 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
| WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| US20070185025A1 (en) * | 2005-09-11 | 2007-08-09 | The Trustees Of Columbia University In The City Of New York | Filoviral immunosuppressive peptides and uses thereof |
| US7947286B2 (en) * | 2005-10-07 | 2011-05-24 | Panthera Biopharma Llc | Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain |
| SG169996A1 (en) * | 2006-02-16 | 2011-04-29 | Us Gov Health & Human Serv | Antiviral agents and vaccines against influenza |
| AU2008262478B9 (en) | 2007-05-29 | 2014-06-19 | Aldevron, L.L.C. | Vectors and methods for genetic immunization |
| WO2009092038A1 (en) * | 2008-01-16 | 2009-07-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza dna vaccination and methods of use thereof |
| CN102202502A (zh) | 2008-06-20 | 2011-09-28 | 巴斯夫欧洲公司 | 包含农药、有机uv光保护过滤剂和涂敷的金属氧化物纳米颗粒的农化配制剂 |
| WO2010048615A2 (en) | 2008-10-24 | 2010-04-29 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services, Center For Disease Control And Prevention | Human ebola virus species and compositions and methods thereof |
| CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| EP2367554A4 (en) | 2008-11-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid reflux inhibitor for the treatment of obesity and diabetes |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| US20120219584A1 (en) | 2009-10-05 | 2012-08-30 | The United States Of America As Represented By The Secretary, Department Of Health | Protection against pandemic and seasonal strains of influenza |
| US9125411B2 (en) | 2010-04-15 | 2015-09-08 | Basf Se | UV absorbers for reducing the E/Z isomerization of pesticides |
| WO2011130627A2 (en) | 2010-04-16 | 2011-10-20 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Chimpanzee adenoviral vector-based filovirus vaccines |
| EP4137137A1 (en) | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| KR101879892B1 (ko) * | 2010-12-14 | 2018-08-17 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신 |
| US9402891B2 (en) * | 2011-06-08 | 2016-08-02 | Ohio State Innovation Foundation | Norovirus immunogens and related materials and methods |
| KR102314421B1 (ko) * | 2011-07-11 | 2021-10-19 | 이노비오 파마수티컬즈, 인크. | 교차-보호성 아레나바이러스 백신 및 이의 사용 방법 |
| WO2013044203A2 (en) | 2011-09-23 | 2013-03-28 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES | Novel influenza hemagglutinin protein-based vaccines |
| EA038594B1 (ru) | 2011-10-28 | 2021-09-21 | Шайр Хьюман Дженетик Терапис, Инк. | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| KR20220012403A (ko) * | 2012-04-12 | 2022-02-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법 |
| EP3054971B1 (en) | 2013-10-11 | 2021-03-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| TWI516602B (zh) | 2013-10-29 | 2016-01-11 | 臺北醫學大學 | 高通量篩選高表現細胞之方法及由其篩選之細胞 |
| US10363301B2 (en) | 2014-05-27 | 2019-07-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Stabilized influenza hemagglutinin stem region trimers and uses thereof |
| CA2959105C (en) * | 2014-09-03 | 2023-10-17 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| BR112017014219A2 (en) | 2014-12-31 | 2018-03-06 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | multivalent nanoparticle-based vaccines |
| JP2018505185A (ja) * | 2015-01-28 | 2018-02-22 | インテグレイテッド バイオセラピューティクス，インコーポレイテッド | ウマ免疫グロブリン組成物及びフィロウイルス媒介疾患の治療のための使用 |
| MX2018006785A (es) | 2015-12-04 | 2018-11-09 | Dana Farber Cancer Inst Inc | Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer. |
| US11459619B2 (en) | 2016-02-08 | 2022-10-04 | The Johns Hopkins University | Handheld nucleic acid-based assay for rapid identification |
| CN110167585B (zh) | 2016-09-02 | 2024-03-08 | 美国卫生与公众服务部 | 稳定化的第2组流感血凝素茎区三聚体及其用途 |
| US11535651B2 (en) | 2017-08-02 | 2022-12-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hepatitis B nanoparticle-based vaccine for influenza virus |
| CA3100070A1 (en) * | 2018-05-18 | 2019-11-21 | Universite Laval | Vectors for dna vaccination |
| CN113423718A (zh) | 2019-02-08 | 2021-09-21 | 美国政府(由卫生和人类服务部的部长所代表) | 基于纳米颗粒的流感病毒疫苗及其用途 |
| EP4637808A1 (en) | 2022-12-22 | 2025-10-29 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Stabilized pfs48/45 proteins and uses thereof |
| WO2025184403A2 (en) * | 2024-02-29 | 2025-09-04 | Memorial Sloan-Kettering Cancer Center | Cell penetrating peptides and methods including the same |
| CN121494944B (zh) * | 2026-01-13 | 2026-05-15 | 中国人民解放军军事科学院军事医学研究院 | 一种马尔堡gp蛋白突变体、dna分子、重组载体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171596B1 (en) * | 1993-12-10 | 2001-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Oligomeric HIV-1 envelope glycoproteins |
| US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
| US6200959B1 (en) * | 1996-12-04 | 2001-03-13 | Powerject Vaccines Inc. | Genetic induction of anti-viral immune response and genetic vaccine for filovirus |
| WO1999032147A1 (en) * | 1997-12-23 | 1999-07-01 | The Regents Of The University Of Michigan | Immunization for ebola virus infection |
| AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
-
2002
- 2002-09-24 CA CA2462455A patent/CA2462455C/en not_active Expired - Lifetime
- 2002-09-24 JP JP2003531968A patent/JP2005508916A/ja active Pending
- 2002-09-24 CA CA 2776391 patent/CA2776391C/en not_active Expired - Lifetime
- 2002-09-24 AU AU2002327049A patent/AU2002327049B2/en not_active Expired
- 2002-09-24 EP EP02761814A patent/EP1504112A4/en not_active Ceased
- 2002-09-24 DE DE60226911T patent/DE60226911D1/de not_active Expired - Lifetime
- 2002-09-24 CA CA2776522A patent/CA2776522C/en not_active Expired - Lifetime
- 2002-09-24 CA CA2776272A patent/CA2776272C/en not_active Expired - Lifetime
- 2002-09-24 ES ES05013732T patent/ES2307093T3/es not_active Expired - Lifetime
- 2002-09-24 WO PCT/US2002/030251 patent/WO2003028632A2/en not_active Ceased
- 2002-09-24 US US10/491,121 patent/US7635688B2/en not_active Expired - Lifetime
- 2002-09-24 AT AT05013732T patent/ATE396739T1/de not_active IP Right Cessation
-
2004
- 2004-11-24 US US10/997,120 patent/US7094598B2/en not_active Expired - Lifetime
-
2005
- 2005-09-27 JP JP2005280131A patent/JP4198148B2/ja not_active Expired - Lifetime
-
2009
- 2009-11-04 US US12/612,579 patent/US8106026B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,621 patent/US8106027B2/en not_active Expired - Fee Related
- 2009-11-04 US US12/612,625 patent/US8124592B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2462455A1 (en) | Development of a preventive vaccine for filovirus infection in primates | |
| JP2023512519A5 (enExample) | ||
| Ulmer et al. | DNA vaccines | |
| Wang et al. | Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium-or aluminum phosphate | |
| US5916879A (en) | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof | |
| GB2610070A (en) | Coronavirus vaccine formulations | |
| JP2004527213A5 (enExample) | ||
| JP2018524393A5 (enExample) | ||
| CN1154069A (zh) | 多表位疫苗 | |
| JP2013501038A5 (enExample) | ||
| CA2293692A1 (en) | Methods and reagents for vaccination which generate a cd8 t cell immune response | |
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| JP2004533208A5 (enExample) | ||
| BR112015023524B1 (pt) | Vírus vaccinia ankara modificado, composição compreendendo o dito vírus e uso do mesmo para primagem ou reforço de uma resposta imune | |
| JP2024508683A5 (enExample) | ||
| JP2003509470A5 (enExample) | ||
| Rollier et al. | Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting | |
| US20090104213A1 (en) | Vaccine for House Dust Mite Allergen Using Naked DNA | |
| CA3010874A1 (en) | Methods and compositions for influenza vaccination | |
| CN1874787B (zh) | 预防/治疗hbv感染和hbv介导疾病的组合物 | |
| JP2024523329A5 (enExample) | ||
| HRP20241297T1 (hr) | Optimizirani sistem domaćina / vektora za stvaranje zaštitnih mono- i viševalentnih podjedinica cjepiva na bazi kvasca kluyveromyces lactis | |
| Ramsay et al. | DNA immunization | |
| JP2020522249A5 (enExample) | ||
| US20220275346A1 (en) | Hantavirus antigenic composition |